According to a new report Global Digital Therapeutics Market, published by KBV research, The Global Digital Therapeutics Market size is expected to reach $14.5 billion by 2027, rising at a market growth of 21.8% CAGR during the forecast period.
The obesity market segment is projected to acquire the second-highest share in the market during the forecast years.

According to the CDC’s National Center for Health Statistics, the frequency of obesity was 42.4% in 2017 & 2018 in the U.S. This surge in the number of obesity cases is anticipated to boost the growth of the segment.

Based on end-use, the patients market segment acquired the maximum revenue share and emerged as the dominated segment in 2020. This segment is estimated to record the promising growth rate over the forecast years. It is because patients are the main users of all these therapeutic healthcare applications and solutions. There number of patients having chronic diseases is constantly increasing, which are bolstering the demand for digital therapeutics solutions across the globe.

Asia-Pacific regional market is projected to witness the prominent CAGR during the forecast period. This growth is attributed to the factors like a huge younger population base that is becoming a target base and the increasing digitalization & urbanization in the region. Additionally, consistent reforms in the nations of the region to cope up with the lack of proper healthcare infrastructure and sustaining significant growth via financial inclusion are estimated to provide lucrative opportunities for the regional market.

Full Report: https://www.kbvresearch.com/digital-therapeutics-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of ResMed, Inc. (Propeller Health), Teladoc Health, Inc. (Livongo Health), Noom, Inc., Omada Health, Inc., Welldoc, Inc., Canary Health, Mango Health, Inc. (TrialCard, Incorporated), 2Morrow, Inc., Pear Therapeutics, Inc., and Mindstrong, Inc.

Global Digital Therapeutics Market Segmentation

By End Use
• Patients
• Providers
• Payers
• Employers
• Others

By Application
• Diabetes
• CNS Disease
• Respiratory Diseases
• Smoking Cessation
• Obesity
• CVD
• others

By Geography

North America
• US
• Canada
• Mexico
• Rest of North America

Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled
• ResMed, Inc. (Propeller Health)
• Teladoc Health, Inc. (Livongo Health)
• Noom, Inc.
• Omada Health, Inc.
• Welldoc, Inc.
• Canary Health
• Mango Health, Inc. (TrialCard, Incorporated)
• 2Morrow, Inc.
• Pear Therapeutics, Inc.
• Mindstrong, Inc.